Additional file 3 of Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

Additional file 3. Fig. S2: The MOA of bsAbs clinical trials. (A-B) The number of MOAs of international companies and China-initiated or involved companies, respectively. (C-D) Surface plot of MOA of international companies and China-initiated or involved companies, respectively

Additional file 2 of Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

Additional file 2. Fig. S1: Geographic distribution of anticancer bsAbs clinical trials. (A) Clinical trials of worldwide companies. (B) Clinical trials of China-initiated or involved R&D pharmaceutical companies

Additional file 1 of Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

Additional file 1. Supplementary Methods and Table S1–6